In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Bicycle Therapeutics (BCYC), with a price target of $38.00. The company’s shares closed last Wednesday at $24.00.
According to TipRanks.com, Olson is a 4-star analyst with an average return of 6.4% and a 48.1% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and Crispr Therapeutics AG.
Bicycle Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $37.80.
See today’s analyst top recommended stocks >>
Based on Bicycle Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $3.84 million and GAAP net loss of $10.14 million. In comparison, last year the company earned revenue of $614K and had a GAAP net loss of $9.48 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
